Shanghai HeartCare Medical Technology (HKG:6609) First Half 2025 Results
Key Financial Results
- Revenue: CN¥185.5m (up 44% from 1H 2024).
- Net income: CN¥50.9m (up from CN¥5.12m loss in 1H 2024).
- Profit margin: 28% (up from net loss in 1H 2024).
- EPS: CN¥1.35 (up from CN¥0.14 loss in 1H 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Shanghai HeartCare Medical Technology shares are up 21% from a week ago.
Risk Analysis
You should learn about the 1 warning sign we’ve spotted with Shanghai HeartCare Medical Technology.
New: Manage All Your Stock Portfolios in One Place
We’ve created the ultimate portfolio companion for stock investors, and it’s free.
• Connect an unlimited number of Portfolios and see your total in one…
